Deals
Jack Ma-Backed Wuxi Diagnostics Considering a Hong Kong IPO
- Company in talks with advisers to raise $400 million in 2022
- Company raised $150 million in series B financing in February
This article is for subscribers only.
Wuxi Diagnostic Investment (Cayman) Ltd., a Shanghai-based integrated diagnostics service platform, is weighing an initial public offering in Hong Kong as soon as next year, people with knowledge of the matter said.
The Chinese firm is in discussions with potential advisers on a Hong Kong listing which could raise about $400 million, said the people, who asked not to be identified as the information is private.